SMARCA4 and cancer: BRG1 inactivation leads to the dysregulation of c-myc activity in the cancer cells, preventing appropriate gene expression control due to the no response towards nuclear receptors such as estrogens, progesterons, corticoids, retinoic acid, and vitamin D3 and sustainability of undifferentiated gene expression programs by cancer cells, thereby promoting cell growth and maintaining an undifferentiated status.